PD-L1 FDA (KEYTRUDA®) for Other Tumor Types
Methodology
Immunohistochemistry (IHC)
Test Description and clinical significance
Disease:
Solid tumors
Programmed cell death ligand 1 (PD-L1) is a predictive biomarker of the response of immunotherapy in some types of cancer. In cancer, the expression of PD-L1 seems to be one of the major immune escape mechanisms. Many studies have shown efficacy of blocking PD-1 or PD-L1 with specific antibodies like pembrolizumab or atezulizumab. In breast cancer, potential response was demonstrated in metastatic triple-negative breast cancers. PD-L1 IHC 22C3 pharmDx can help identify gastric or GEJ adenocarcinoma patients for treatment with KEYTRUDA. PD-L1 is a proven biomarker for patient response to KEYTRUDA in certain tumors Upregulation of PD-L1 may allow cancers to evade the host immune system. Upregulation of PD-L1 on immune cells (especially myeloid cells) can also lead to formation of an immunosuppressive environment in a highly localized manner that also allow the cancer cells to proliferate.
Specimen Requirements
Collection:
FFPE/un-stained slides/Fresh tissue in formalin
Stability:
Room temperature
Unacceptable Conditions:
Unlabeled specimen/specimen left unfixed
for extended periods
Storage & Transport
Room Temperature
CPT(s)
88360
New York Approved
NO
TAT
2 Days
*The CPT codes provided are for informational purposes only and are based on AMA guidelines The billing party is solely responsible for correct CPT coding.
